Albumedix Ltd. Appoints Joanna Hay as Vice President of Commercial Operations01 Sep 2021
PRESS RELEASE: Nottingham, UK, 1 September 2021 – Albumedix Ltd. (‘Albumedix’), a globally recognized leader in albumin-based enabling solutions for advanced therapies and next-generation biopharmaceuticals, announced today the appointment of Joanna Hay as Vice President of Commercial Operations, effective as of September 1st, 2021.
Joanna Hay has been with Albumedix since 2007 and in that time has held notable positions in both technical and commercial capacities, most recently as Head of Sales & Business Development in Europe.
As the VP of Commercial Operations, Joanna will be responsible for market engagement and the commercialization of Albumedix’ albumin-based solutions, enabling clients through their development and beyond. She will become a key member of Albumedix’ executive management reporting directly to Albumedix’ Chief Executive Officer, Jonas Skjødt Møller.
Commenting on the appointment, Møller comments; “Having worked with Jo for close to 10 years, I am delighted to see her step into the role as VP of Commercial Operations and look forward to having her join the management team. Jo brings a strong ability to build partnerships and deliver hand-held solutions across virtually all verticals of the life science industry. Combined with her fantastic personality, I am convinced Jo will add valuable contributions and help further accelerate our ambitious growth strategy.”
Joanna has more than 15 years' experience in the life science industry, including a PhD in Biochemistry. Joanna will continue to be based in the UK and will assume the position as of September 1st, 2021, succeeding Gregor Kawaletz, who will pursue his career outside the company.
Commenting on her new appointment, Joanna said: “I am thrilled and honoured to take on this new role; joining Albumedix’ experienced management team and leading our talented commercial group at such an exciting time. Albumedix is experiencing extraordinary growth, in particular in the vaccine and advanced therapy space where our solutions help these transformative pharmaceuticals into viable therapies to the benefits of patients worldwide”.
About Albumedix – Dedicated to Better Health
Albumedix is a science-driven, life-science company focused on enabling the creation of superior biopharmaceuticals utilizing our recombinant human albumin products, services, and technologies. We believe in empowering excellence to enable advanced therapies and facilitate otherwise unstable drug candidates reach patients worldwide. We are proud to be recognized as the world leader in recombinant human albumin with products and technologies used in clinical and marketed drugs by pharmaceutical and medical device companies worldwide. Headquartered in Nottingham, England with more than 100 people all committed to improving patient quality of life. We are just as passionate about albumin and albumin-enabled therapies today as we were when we started more than 35 years ago. Learn more today.
For media enquiries, please contact:
Sian Gilfillan, Marketing and Communications Manager, BD@albumedix.com